Surgical outcomes of Ex-PRESS® mini glaucoma shunt implantation [Ex-PRESS® mini glokom İmplant cerrahisi sonuçlarımız]

dc.contributor.authorOkka M.
dc.contributor.authorBitirgen G.
dc.contributor.authorKerimoğlu H.
dc.contributor.authorBozkurt B.
dc.contributor.authorYumak Erkoça H.
dc.date.accessioned2020-03-26T18:58:55Z
dc.date.available2020-03-26T18:58:55Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: To evaluate intraocular pressure (IOP) lowering effect and safety of Ex-PRESS® mini glaucoma drainage implant (Alcon, Fort Worth, TX) for the surgical treatment of glaucoma. Material and Methods: The data of the subjects who underwent Ex-PRESS® mini glaucoma shunt (P-50) implantation surgery in 2011 and 2012 were retrospectively reviewed. IOP before and after the treatment, visual acuity, the number of medications and complications were analyzed. Success was defined as final IOP of 6-21 mmHg with or without antiglaucomatous medications. Results: Thirty two eyes of 32 patients were included in the study. The mean age of patients and mean follow-up time were 54.43±14.56 years (range 20-77 years) and 6.34±2.95 months (range 3-16 months), respectively. Mean pretreatment IOP was 30.71±4.72 mmHg, while it was 13.21±3.51 mmHg (p<0.001) at the first week, 14.46±4.08 mmHg (p<0.001) in the first month, 14.37±2.93 mmHg (p<0.001) in the third month, 13.78±2.98 mmHg (p<0.001) in the sixth month, and 14.53±2.27 mmHg (p<0.001) in the last visit. An IOP less than 21 mmHg was achieved in all eyes in the last visit. The median value of preoperative total antiglaucomatous medications was 4.0 (3.0-5.0), however topical medications were discontinued in 81.3% of patients in the last visit. There were no complications during the follow-up period except one case of early postoperative choroidal effusion. Conclusion: Ex-PRESS® mini glaucoma shunt implantation is supposed to be an effective and safe method for the surgical treatment of glaucoma. It also helped to reduce the number of antiglaucoma medications, thus improving both the quality of life of the patients and their compliance to therapy. © 2014 by Türkiye Klinikleri.en_US
dc.identifier.doi10.5336/medsci.2013-36700en_US
dc.identifier.endpage297en_US
dc.identifier.issn1300-0292en_US
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage293en_US
dc.identifier.urihttps://dx.doi.org/10.5336/medsci.2013-36700
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31343
dc.identifier.volume34en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofTurkiye Klinikleri Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectGlaucomaen_US
dc.subjectGlaucoma drainage implantsen_US
dc.subjectIntraocular pressureen_US
dc.titleSurgical outcomes of Ex-PRESS® mini glaucoma shunt implantation [Ex-PRESS® mini glokom İmplant cerrahisi sonuçlarımız]en_US
dc.typeArticleen_US

Dosyalar